{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T15:28:19Z","timestamp":1778513299556,"version":"3.51.4"},"reference-count":38,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100017594","name":"Medical Science and Technology Project of Zhejiang Province","doi-asserted-by":"publisher","award":["2024KY730"],"award-info":[{"award-number":["2024KY730"]}],"id":[{"id":"10.13039\/501100017594","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017594","name":"Medical Science and Technology Project of Zhejiang Province","doi-asserted-by":"publisher","award":["2025KY566"],"award-info":[{"award-number":["2025KY566"]}],"id":[{"id":"10.13039\/501100017594","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.bbadis.2025.168128","type":"journal-article","created":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T14:25:57Z","timestamp":1764858357000},"page":"168128","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Vitexin targets USP49-GRPR deubiquitination axis in medullary thyroid carcinoma therapy"],"prefix":"10.1016","volume":"1872","author":[{"given":"Qing","family":"Xia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuai","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qinmei","family":"Lai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanlin","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbadis.2025.168128_bb0005","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1200\/JCO.21.01329","article-title":"International medullary thyroid carcinoma grading system: a validated grading system for medullary thyroid carcinoma","volume":"40","author":"Xu","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbadis.2025.168128_bb0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12022-023-09753-5","article-title":"Update on C-cell neuroendocrine neoplasm: prognostic and predictive histopathologic and molecular features of medullary thyroid carcinoma","volume":"34","author":"Jung","year":"2023","journal-title":"Endocr. Pathol."},{"key":"10.1016\/j.bbadis.2025.168128_bb0015","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1186\/s12964-024-01837-x","article-title":"Molecular genetics, therapeutics and RET inhibitor resistance for medullary thyroid carcinoma and future perspectives","volume":"22","author":"Zhang","year":"2024","journal-title":"Cell Commun. Signal"},{"key":"10.1016\/j.bbadis.2025.168128_bb0020","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16203469","article-title":"Holomics and artificial intelligence-driven precision oncology for medullary thyroid carcinoma: addressing challenges of a rare and aggressive disease","volume":"16","author":"Luvhengo","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bbadis.2025.168128_bb0025","doi-asserted-by":"crossref","DOI":"10.1093\/ejendo\/lvac009","article-title":"Other markers of medullary thyroid cancer, not only calcitonin","volume":"188","author":"Censi","year":"2023","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.bbadis.2025.168128_bb0030","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1097\/CM9.0000000000000160","article-title":"Comprehensive evaluation of medullary thyroid carcinoma before surgery","volume":"132","author":"Guo","year":"2019","journal-title":"Chin. Med. J."},{"key":"10.1016\/j.bbadis.2025.168128_bb0035","doi-asserted-by":"crossref","first-page":"R85","DOI":"10.1530\/ERC-21-0368","article-title":"Metastatic medullary thyroid carcinoma: a new way forward","volume":"29","author":"Angelousi","year":"2022","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.bbadis.2025.168128_bb0040","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/nrendo.2016.11","article-title":"A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma","volume":"12","author":"Romei","year":"2016","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.bbadis.2025.168128_bb0045","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/s41580-019-0099-1","article-title":"Breaking the chains: deubiquitylating enzyme specificity begets function","volume":"20","author":"Clague","year":"2019","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.bbadis.2025.168128_bb0050","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nrd.2017.152","article-title":"Deubiquitylating enzymes and drug discovery: emerging opportunities","volume":"17","author":"Harrigan","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bbadis.2025.168128_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114497","article-title":"Novel insight on GRP\/GRPR axis in diseases","volume":"161","author":"Sun","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bbadis.2025.168128_bb0060","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1093\/annonc\/mdm058","article-title":"Gastrin-releasing peptide receptor as a molecular target in experimental anticancer therapy","volume":"18","author":"Cornelio","year":"2007","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bbadis.2025.168128_bb0065","doi-asserted-by":"crossref","DOI":"10.3390\/cells13010029","article-title":"Targeting the Ubiquitin-Proteasome System and Recent Advances in Cancer Therapy","volume":"13","author":"Spano","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.bbadis.2025.168128_bb0070","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41392-020-0107-0","article-title":"The role of ubiquitination in tumorigenesis and targeted drug discovery","volume":"5","author":"Deng","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bbadis.2025.168128_bb0075","doi-asserted-by":"crossref","DOI":"10.3390\/ph14090848","article-title":"Ubiquitin-Specific Proteases: Players in Cancer Cellular Processes","volume":"14","author":"Cruz","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.bbadis.2025.168128_bb0080","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1186\/s13046-023-02805-y","article-title":"Targeting ubiquitin specific proteases (USPs) in cancer immunotherapy: from basic research to preclinical application","volume":"42","author":"Gao","year":"2023","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.bbadis.2025.168128_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbamcr.2025.119908","article-title":"The key vulnerabilities and therapeutic opportunities in the USP7-p53\/MDM2 axis in cancer","volume":"1872","author":"Saha","year":"2025","journal-title":"Biochim. Biophys. Acta, Mol. Cell Res."},{"key":"10.1016\/j.bbadis.2025.168128_bb0090","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3389\/fcell.2020.00233","article-title":"Targeting USP7-mediated deubiquitination of MDM2\/MDMX-p53 pathway for cancer therapy: are we there yet?","volume":"8","author":"Qi","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.bbadis.2025.168128_bb0095","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1080\/13880209.2023.2190774","article-title":"Vitexin suppresses the proliferation, angiogenesis and stemness of endometrial cancer through the PI3K\/AKT pathway","volume":"61","author":"Liang","year":"2023","journal-title":"Pharm. Biol."},{"key":"10.1016\/j.bbadis.2025.168128_bb0100","doi-asserted-by":"crossref","first-page":"441","DOI":"10.3892\/ijmm.2013.1587","article-title":"Purified vitexin compound 1 inhibits growth and angiogenesis through activation of FOXO3a by inactivation of Akt in hepatocellular carcinoma","volume":"33","author":"Wang","year":"2014","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.bbadis.2025.168128_bb0105","doi-asserted-by":"crossref","first-page":"439","DOI":"10.5230\/jgc.2021.21.e40","article-title":"Vitexin Inhibits gastric cancer growth and metastasis through HMGB1-mediated Inactivation of the PI3K\/AKT\/mTOR\/HIF-1alpha signaling pathway","volume":"21","author":"Zhou","year":"2021","journal-title":"J Gastric Cancer"},{"key":"10.1016\/j.bbadis.2025.168128_bb0110","doi-asserted-by":"crossref","first-page":"99","DOI":"10.2174\/156720208784310240","article-title":"Gastrin-releasing peptide receptors regulate proliferation of C6 Glioma cells through a phosphatidylinositol 3-kinase-dependent mechanism","volume":"5","author":"Flores","year":"2008","journal-title":"Curr. Neurovasc. Res."},{"key":"10.1016\/j.bbadis.2025.168128_bb0115","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.peptides.2017.07.008","article-title":"Gastrin-releasing peptide and its receptor increase arthritis fibroblast-like synoviocytes invasiveness through activating the PI3K\/AKT pathway","volume":"95","author":"Clarimundo","year":"2017","journal-title":"Peptides"},{"key":"10.1016\/j.bbadis.2025.168128_bb0120","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0277956","article-title":"Anti-GRP-R monoclonal antibody antitumor therapy against neuroblastoma","volume":"17","author":"Qiao","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.bbadis.2025.168128_bb0125","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/j.yexcr.2007.01.016","article-title":"Gastrin-releasing peptide activates Akt through the epidermal growth factor receptor pathway and abrogates the effect of gefitinib","volume":"313","author":"Liu","year":"2007","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.bbadis.2025.168128_bb0130","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S2213-8587(24)00200-6","article-title":"Aberrant hormone receptors regulate a wide spectrum of endocrine tumors","volume":"12","author":"Lacroix","year":"2024","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.bbadis.2025.168128_bb0135","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s10020-023-00763-x","article-title":"G protein-coupled estrogen receptor activates PI3K\/AKT\/mTOR signaling to suppress ferroptosis via SREBP1\/SCD1-mediated lipogenesis","volume":"30","author":"Chen","year":"2024","journal-title":"Mol. Med."},{"key":"10.1016\/j.bbadis.2025.168128_bb0140","article-title":"A Vision for Gastrin-Releasing Peptide Receptor Targeting for Imaging and Therapy: Perspective from Academia and Industry","author":"Morgat","year":"2025","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.bbadis.2025.168128_bb0145","doi-asserted-by":"crossref","DOI":"10.3390\/cells13242128","article-title":"GRPR Drives Metastasis via CRABP2 and FNDC4 Pathways in Lung Adenocarcinoma","volume":"13","author":"Kim","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.bbadis.2025.168128_bb0150","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1016\/j.scib.2024.04.017","article-title":"P53 upregulation by USP7-engaging molecular glues","volume":"69","author":"Li","year":"2024","journal-title":"Sci Bull (Beijing)"},{"key":"10.1016\/j.bbadis.2025.168128_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.105273","article-title":"Recent advances on the intervention sites targeting USP7-MDM2-p53 in cancer therapy","volume":"116","author":"Harakandi","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bbadis.2025.168128_bb0160","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.7150\/ijbs.68179","article-title":"Flap endonuclease 1 facilitated hepatocellular carcinoma progression by enhancing USP7\/MDM2-mediated P53 inactivation","volume":"18","author":"Bian","year":"2022","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.bbadis.2025.168128_bb0165","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1038\/s41388-022-02267-0","article-title":"USP49 mediates tumor progression and poor prognosis through a YAP1-dependent feedback loop in gastric cancer","volume":"41","author":"Liu","year":"2022","journal-title":"Oncogene"},{"key":"10.1016\/j.bbadis.2025.168128_bb0170","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/s41419-022-04675-2","article-title":"Fbxo45 facilitates pancreatic carcinoma progression by targeting USP49 for ubiquitination and degradation","volume":"13","author":"Wu","year":"2022","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bbadis.2025.168128_bb0175","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/kjm2.12073","article-title":"Ubiquitin specific peptidase 49 inhibits non-small cell lung cancer cell growth by suppressing PI3K\/AKT signaling","volume":"35","author":"Shen","year":"2019","journal-title":"Kaohsiung J. Med. Sci."},{"key":"10.1016\/j.bbadis.2025.168128_bb0180","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s11864-021-00867-8","article-title":"Therapeutic advances in the management of patients with advanced RET fusion-positive non-small cell lung cancer","volume":"22","author":"Sun","year":"2021","journal-title":"Curr. Treat. Options in Oncol."},{"key":"10.1016\/j.bbadis.2025.168128_bb0185","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/s41568-023-00633-y","article-title":"Deubiquitinases in cancer","volume":"23","author":"Dewson","year":"2023","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbadis.2025.168128_bb0190","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1016\/j.drudis.2022.06.009","article-title":"Deubiquitinating enzymes: promising targets for drug resistance","volume":"27","author":"Ge","year":"2022","journal-title":"Drug Discov. Today"}],"container-title":["Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0925443925004788?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0925443925004788?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T09:31:17Z","timestamp":1769506277000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0925443925004788"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S0925443925004788"],"URL":"https:\/\/doi.org\/10.1016\/j.bbadis.2025.168128","relation":{},"ISSN":["0925-4439"],"issn-type":[{"value":"0925-4439","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vitexin targets USP49-GRPR deubiquitination axis in medullary thyroid carcinoma therapy","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbadis.2025.168128","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"168128"}}